Agammaglobulinemia

Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)

NCT00168012 | PHASE 3 | INTERVENTIONAL

The purpose of this study is to demonstrate the effect of IVIG-F10 on the prevention of serious bacterial infections in patients with primary immunodeficiency. As secondary endpoints the rate of overall infections, the tolerability and safety of IVIG-F10 are studied.

0 Sites

42 Participants

Recruiting

3 Years to 70 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Study Eligibility Criteria

Inclusion Criteria

* Patients with primary immunodeficiency
* Regular IVIG therapy for at least 6 months prior to receiving IVIG-F10
Key

Exclusion Criteria

* Allergic reactions to immunoglobulins or other blood products
* Steroids (oral and parenteral, daily ≥0.15 mg of prednisone equivalent/kg/day
* History of cardiac insufficiency
* Epilepsia

Additional Studies

Additional studies can be found at ClinicalTrials.gov